The U.S. Food and Drug Administration is requiring manufacturers of GLP-1 medicines to add safety-label warnings about a potential increased risk of nonarteritic anterior ischemic optic neuropathy (NAION), a rare condition that can cause permanent vision loss. Several medical studies found elevated risk among users; close to 30 million Americans take the drugs.
Reporting from 3 identified publishers across this event arc.
These publishers contributed reporting to the broader event history. Not every source addresses the specific development described above.
How this brief is built: The BriefBrief correlates multiple sources into one evolving event brief, updated as new facts emerge.
Page 10 of 21922
Same format. Every time.
Continue reading — sign in or create a free account with
